ACT With Chloroquine, Amodiaquine & Sulphadoxine-pyrimethamine in Pakistan

• Status: Completed
• Trial end date: 2004-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Chloroquine resistant falciparum malaria in Pakistan is prevalent in every malarious area examined. Resistance to the favoured second-line treatment, sulphadoxine-pyrimethamine S/P is rising fast. To avert a repetition of the resistance catastrophe that occurred in SE Asia it is critical to preserve the effective life of SP by using it in combination with artesunate. Efficacy of ACT with artesunate in combination with chloroquine, SP or amodiaquine for treatment of malaria (falciparum or vivax) will be examined in malaria patients in Pakistan.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gates Malaria Partnership; London School of Hygiene and Tropical Medicine
• Collaborators: HealthNet TPO; Malaria Control Program, Directorate of Malaria Control, Pakistan; Pakistan Directorate of Malaria Control; United Nations High Commissioner for Refugees; World Health Organization
• Treatments: Amodiaquine; Artesunate; Chloroquine; Chloroquine diphosphate; Fanasil, pyrimethamine drug combination; Primaquine; Pyrimethamine; Sulfadoxine

Criteria

Inclusion Criteria:

• adults or children > 5 yrs

• weight > 5 kg

• monoinfection with P. falciparum or P. vivax

• history of recent fever

• consent from patient or parent.

Exclusion Criteria:

• patients with signs of severe malaria.